However, a challenge to this therapeutic strategy is the substantial variability observed in HIV-1 gp120 although patients heterozygous for a Δ32 deletion in CCR5, which introduces a premature stop codon, exhibit slower disease progression whilst homozygotes are resistant to infection.12,440–442. The gene discussed is CCR5; the disease is infection.